Detection of SARS-CoV-2 by Mass Spectrometry

Petra Wandernoth; Katharina Kriegsmann; Jörg Kriegsmann; Mark Kriegsmann

doi:10.1007/978-1-0716-2111-0_12

Detection of SARS-CoV-2 by Mass Spectrometry

Methods Mol Biol. 2022:2452:183-196. doi: 10.1007/978-1-0716-2111-0_12.

Authors

Petra Wandernoth¹, Katharina Kriegsmann², Jörg Kriegsmann^{1

3

4}, Mark Kriegsmann^{5

6}

Affiliations

¹ Molecular Pathology Trier, Trier, Germany.
² Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
³ Danube Private University Krems, Krems, Austria.
⁴ Proteopath Trier, Trier, Germany.
⁵ Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany. mark.kriegsmann@med.uni-heidelberg.de.
⁶ Member of the German Centre for Lung Research (DZL), Translational Lung Research Centre Heidelberg, Heidelberg, Germany. mark.kriegsmann@med.uni-heidelberg.de.

PMID: 35554908
DOI: 10.1007/978-1-0716-2111-0_12

Abstract

Amplification of viral ribonucleic acid by real-time reverse transcriptase polymerase chain reaction is the gold standard to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, alternative reliable, fast, and cost-effective methods for the detection of SARS-CoV-2 are still needed. In this chapter, the mass spectrometry-based detection of amplified polymerase chain reaction products of SARS-CoV-2 genes from oral or nasopharyngeal swabs is described. The respective SARS-CoV-2 test has previously been shown to meet standard quality criteria and was therefore approved by the authorities in Europe and the USA.

Keywords: COVID-19; Mass Spectrometry; MassARRAY; SARS-CoV-2.

MeSH terms

COVID-19* / diagnosis
Humans
Mass Spectrometry
Nasopharynx
RNA, Viral / analysis
RNA, Viral / genetics
Real-Time Polymerase Chain Reaction
SARS-CoV-2* / genetics

Substances

RNA, Viral